Multi-Billion Global Market with First Mover Advantage in LatAm
Our goals go beyond building a great cultivation facility. We aim to become the global leader in creating high quality, consumer packaged goods (CPG) cannabis brands around the world.
With regulatory change happening rapidly across Latin America, eleven countries have legalized medical cannabis, and three have decriminalized the use of personal amounts. With operations in Colombia, a presence in Mexico, Uruguay, Chile and Peru, and access to Brazil, Khiron Life Sciences is positioned to be a leading, established player providing investor exposure to the Latin American market.
Our experienced European management team provides Khiron with a strong cannabis industry background in capital markets and regulatory matters. The company currently has fulfilled E.U. cosmetic product regulatory requirements for seven Kuida® products to be launched in the UK. The company has also entered into an agreement to be the exclusive Latin American provider of cannabis medicines to Project Twenty21 in the UK. The company is set for growth in Europe, with significant near- and long-term revenue opportunities thatvalidate the company's management, execution abilities and global strategy.